Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
1997 1
1999 1
2000 1
2002 1
2003 1
2004 3
2005 5
2006 1
2007 4
2008 4
2009 4
2010 3
2011 5
2012 7
2013 5
2014 3
2015 5
2016 4
2017 6
2018 5
2019 11
2020 9
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

84 results
Results by year
Filters applied: . Clear all
Page 1
A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.
Chefetz I, Grimley E, Yang K, Hong L, Vinogradova EV, Suciu R, Kovalenko I, Karnak D, Morgan CA, Chtcherbinine M, Buchman C, Huddle B, Barraza S, Morgan M, Bernstein KA, Yoon E, Lombard DB, Bild A, Mehta G, Romero I, Chiang CY, Landen C, Cravatt B, Hurley TD, Larsen SD, Buckanovich RJ. Chefetz I, et al. Among authors: buckanovich rj. Cell Rep. 2019 Mar 12;26(11):3061-3075.e6. doi: 10.1016/j.celrep.2019.02.032. Cell Rep. 2019. PMID: 30865894 Free PMC article.
Immunotherapy Advances for Epithelial Ovarian Cancer.
Hartnett EG, Knight J, Radolec M, Buckanovich RJ, Edwards RP, Vlad AM. Hartnett EG, et al. Among authors: buckanovich rj. Cancers (Basel). 2020 Dec 11;12(12):3733. doi: 10.3390/cancers12123733. Cancers (Basel). 2020. PMID: 33322601 Free PMC article. Review.
Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer.
Brown JR, Chan DK, Shank JJ, Griffith KA, Fan H, Szulawski R, Yang K, Reynolds RK, Johnston C, McLean K, Uppal S, Liu JR, Cabrera L, Taylor SE, Orr BC, Modugno F, Mehta P, Bregenzer M, Mehta G, Shen H, Coffman LG, Buckanovich RJ. Brown JR, et al. Among authors: buckanovich rj. JCI Insight. 2020 Jun 4;5(11):e133247. doi: 10.1172/jci.insight.133247. JCI Insight. 2020. PMID: 32369446 Free PMC article. Clinical Trial.
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA. Liu JF, et al. Among authors: buckanovich rj. Ann Oncol. 2019 Apr 1;30(4):551-557. doi: 10.1093/annonc/mdz018. Ann Oncol. 2019. PMID: 30753272 Free PMC article. Clinical Trial.
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Liu JF, et al. Among authors: buckanovich rj. Lancet Oncol. 2014 Oct;15(11):1207-14. doi: 10.1016/S1470-2045(14)70391-2. Epub 2014 Sep 10. Lancet Oncol. 2014. PMID: 25218906 Free PMC article. Clinical Trial.
Regulation and pharmacological targeting of RAD51 in cancer.
Grundy MK, Buckanovich RJ, Bernstein KA. Grundy MK, et al. Among authors: buckanovich rj. NAR Cancer. 2020 Sep;2(3):zcaa024. doi: 10.1093/narcan/zcaa024. Epub 2020 Sep 25. NAR Cancer. 2020. PMID: 33015624 Free PMC article.
The double edge sword of fibrosis in cancer.
Chandler C, Liu T, Buckanovich R, Coffman LG. Chandler C, et al. Among authors: buckanovich r. Transl Res. 2019 Jul;209:55-67. doi: 10.1016/j.trsl.2019.02.006. Epub 2019 Feb 21. Transl Res. 2019. PMID: 30871956 Free PMC article. Review.
NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer.
Cole AJ, Iyengar M, Panesso-Gómez S, O'Hayer P, Chan D, Delgoffe GM, Aird KM, Yoon E, Bai S, Buckanovich RJ. Cole AJ, et al. Among authors: buckanovich rj. JCI Insight. 2020 Apr 9;5(7):e131486. doi: 10.1172/jci.insight.131486. JCI Insight. 2020. PMID: 32182216 Free PMC article.
84 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page